The University of Chicago Cancer Research Center (UCCRC) is submitting this competitive renewal application for its Cancer Center Support Grant for years 33-37. The mission of the UCCRC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer. Our cancer research programs emphasize translational and interdisciplinary research, and we pursue this goal by promoting collaboration among a diverse and dedicated team of outstanding basic, translational, clinical, and population researchers. The 198 members of the UCCRC are organized into six established programs, all with a translational focus (Cell Signaling and Gene Regulation;Molecular Genetics and Hematopoiesis;Immunology and Cancer;Clinical and Experimental Therapeutics;Advanced Imaging, and Cancer Risk and Prevention). Clinical research is a major focus of multidisciplinary activity at the UCCRC. In 2006, over 1000 individual patients were accrued to therapeutic protocols supported, in part, by NCI cooperative agreements and contracts to conduct phase I, phase II, and phase III clinical trials. The UCCRC is the host institution for the Cancer and Leukemia Group B, a full member of the Gynecologic Oncology Group, and the Children's Oncology Group, and participates in the Radiation Therapy Oncology Group, American College of Surgeons Oncology Group, and National Surgical Adjuvant Breast and Bowel Program studies. Funds are requested in this application for Senior and Program Leaders, Planning and Evaluation, Developmental Funds, Administration, Protocol-Specific Research, the Protocol Review and Monitoring System, and 13 shared resources (Genomics;Fitch Monoclonal Antibody;Flow Cytometry;Immunohistochemistry;Human Immunologic Monitoring;Integrated Microscopy;Magnetic Resonance Imaging and Spectroscopy;Scientific Visualization and Image Analysis;Transgenic Mouse/Embryonic Stem Cell;Human Tissue Resource;Pharmacology;Biostatistics;and Cancer Clinical Trials Office).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-37
Application #
8244558
Study Section
Special Emphasis Panel (ZCA1-RTRB-N (J1))
Program Officer
Shafik, Hasnaa
Project Start
1997-09-01
Project End
2013-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
37
Fiscal Year
2012
Total Cost
$4,138,729
Indirect Cost
$1,446,761
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Webber, Jemma L; Zhang, Jie; Massey, Alex et al. (2018) Collaborative repressive action of the antagonistic ETS transcription factors Pointed and Yan fine-tunes gene expression to confer robustness in Drosophila. Development 145:
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5
Boisclair Lachance, Jean-François; Webber, Jemma L; Hong, Lu et al. (2018) Cooperative recruitment of Yan via a high-affinity ETS supersite organizes repression to confer specificity and robustness to cardiac cell fate specification. Genes Dev 32:389-401
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Maron, Steven B; Alpert, Lindsay; Kwak, Heewon A et al. (2018) Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 8:696-713

Showing the most recent 10 out of 668 publications